A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

The study, presented at the American Academy of Ophthalmology (AAO) Annual meeting, reported that 88% of patients treated with EYLEA HD were maintained on a dosing interval of 12 weeks or more at ...

and REGN's patents protect EYLEA HD until at least 2037. Moreover, Dupixent and Libtayo remain strong growth drivers, contributing significantly to Regeneron’s revenue with expanding approvals ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today shared positive results from a three-year extension study of the Phase 3 PHOTON trial, demonstrating that EYLEA HD ...